Pay in 4 interest-free payments of $7.17 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Dosing errors from multidose vials and incorrect syringes have caused hospitalizations for severe nausea, vomiting, dehydration, and pancreatitis
Implications for Practice Due to the established connection between GLP-1 agonists and DR, optometrists should err on the side of caution and be in contact with primary care physicians on whether GLP-1/gastric inhibitory polypeptide (GIP) agonists should be prescribed in patients who have existing DR
Clinical trials have shown that Semaglutide use is associated with a reduced incidence of cardiovascular events, including mortality, heart attack, and stroke in individuals with obesity
This spike is driven by high utilization and complex PBM models, where opaque pricing and rebate structures can limit employers' ability to capture the lowest net drug prices
Quick eligibility & safety refresher (because expectations depend on fit) Source: FDA Who should consider GLP-1 medicines
